Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA and Industry Devise "Least Burdensome" Device Approval Strategy

This article was originally published in The Silver Sheet

Executive Summary

IMPLEMENTATION OF THE "LEAST BURDENSOME" CONCEPT prescribed by Sec. 205 of the FDA Modernization Act will affect "virtually all" of FDA's medical device premarket approval activities, agency officials pledge. Industry hopes the FDAMA provisions, which require the agency to consider the "least burdensome" means for making PMA and 510(k) determinations, will foster quicker product development times. FDA and industry recently released a least burdensome "concept and principles" document that recommends exploring alternatives to randomized, controlled trials to support product approvals. A least burdensome approach is expected to foster greater interaction between product sponsors and FDA reviewers and increased use of new communication tools provided under FDAMA. WARNING LETTERS: FDA requests outside certification from Somnus Medical for corrective actions to address QS reg deficiencies; Datascope VasoSeal ES complication rate claims are "false and misleading," agency says

You may also be interested in...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts